← Vaxcyte, Inc. (PCVX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Vaxcyte, Inc. (PCVX)
Biological Products, (No Diagnostic Substances) · market cap $8.3B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
7
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Vaxcyte, Inc. (PCVX) is a clinical-stage vaccine company focused on pneumococcal conjugate vaccines, with a 31-valent PCV (VAX-31) as its lead asset in Phase 3 and a 24-valent PCV (VAX-24) in Phase 2. The company has no revenue, burns roughly $794M annually in R&D, and carries a reported cash runway of approximately 2.8 months — implying near-certain near-term capital requirements despite an $8.4B market cap.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
- 2027-01-15 (est.)Phase 3 · PCV20imp 9/10
- 2027-03-15 (est.)Phase 3 · 31-valent pneumococcal conjugate vaccineimp 9/10
- 2027-06-30 (est.)Phase 3imp 6/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| 0.5 mL of the low dose VAX-31 | Phase 2 | Pneumococcal Vaccines |
| 24 valent pneumococcal conjugate vaccine | Phase 2 | Pneumococcal Vaccines |
| 0.5 ml dose of 1.1 mcg VAX-24 | Phase 2 | Pneumococcal Vaccines |
| 24-Valent Pneumococcal Conjugate Vaccine | Phase 2 | Pneumococcal Vaccines |
| 31 valent pneumococcal conjugate vaccine | Phase 3 | Pneumococcal Vaccines |
| PCV20 | Phase 3 | Pneumococcal Vaccines |
| 31-valent pneumococcal conjugate vaccine | Phase 3 | Pneumococcal Vaccines |
Price & technical context
3-month
-4.0%
6-month
-4.2%
12-month
+55.6%
52-wk range
$38.03–$63.30
vs 50-day MA
-4.2%
vs 200-day MA
+1.8%
Realized vol
44.6%
Max drawdown
-76.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PCVX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.